Companies In The Bi-Specific MAbs Market Are Investing In Strategic Collaborations And Partnerships 1
Global Bi-Specific MAbs Market, Forecast Market Size, 2019 – 2023, $ Billion
The Business Research Company’s Global Bi-Specific MAbs Market Report 2020-30: Covid 19 Growth And Change; Segments Covered: 1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 2) By Product Type: In Vivo, In Vitro 3) By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others 4) By End Use: Hospitals, Research Institutes, Others

Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment.

The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4, along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.

The global bi-specific MAbs market was valued at about $1.56 billion in 2019 and is expected to grow to $2.93 billion in 2020 at a compound annual growth rate (CAGR) of 87.6%. The COVID-19 restrictions caused a slowdown in growth from 2018 due to missed patient visits affecting potential new patients who deferred the care, whereas existing patients remained on their treatment. However, with the sales beginning to recover slowly, the global bi-specific MAbs market is expected to stabilize and reach $6.12 billion by 2023 at a CAGR of 27.8%.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression.

According to the World Health Organization, cancer is the second leading cause of death worldwide and was responsible for an estimated 9.8 million deaths in 2018. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

Here Is A List Of Similar Reports By The Business Research Company:

Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change

Monoclonal Antibodies (MAbS) Global Market Report 2020-30: Covid 19 Impact And Recovery

Conjugated Monoclonal Antibodies Global Market Report 2020-30: Covid 19 Growth And Change

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
City: London
State: Greater London
Country: United Kingdom